Review Article
Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?
Table 1
Genetic mutations and corresponding current and future targeted therapies.
| Pathway | Target | Therapy |
| MAP-kinase | Receptor tyrosine kinase | Imatinib | Dasatinib | Nilotinib | Masitinib | BRAF | GSK2118436 | Vemurafenib | NRAS | Sorafenib | Tipifamib | CRAS | Lonafamib | RAF265 |
| PI3AK | mTor | Sirolimus | Temsirolimus | Everolimus | PI3, AKT | GDC0941, GSK2126458, BEZ235, BKM120, XL765, MK2206, GSK 690693 |
| MITF | CDK2, HDAC | SCH727965, panobinostat |
| WNT | B catenin | Small molecular antagonists | RNA aptamers |
|
|